


RESEARCH

Open Access



Relationship of serum homocysteine and vitamin D with positive, negative, and extrapyramidal symptoms in schizophrenia: a case–control study in Iran

Najmeh Shahini¹, Seyed Mohammad Mousavi Zade Jazayeri^{2*} , Reza Jahanshahi² and Abdurrahman Charkazi³

Abstract

Background: Schizophrenia is a devastating condition characterized by frequent recurrences, cognitive decline, and emotional and functional disabilities. This condition includes positive and negative symptoms and cognitive impairments resistant to drug treatment. According to studies, many biomarkers can affect this disorder. However, there is little information about vitamin D and homocysteine levels in patients with disease complications. We aimed to investigate this relationship in schizophrenia.

Method: In this case–control study, 33 patients with schizophrenia and 33 healthy individuals were enrolled from Golestan, the north of Iran, in 2021. Blood samples were taken from all participants to assess vitamin D and homocysteine serum levels. In addition, schizophrenic patients completed the Positive And Negative Syndrome Scale (PANSS) and Simpson-Angus Extrapyramidal Side Effects Scale (SAS). Data analysis was performed at a significance level of 0.05 using SPSS 16 software.

Results: Of the 66 participants, 66.7% had vitamin D deficiency, and 71.2% had normal homocysteine levels. However, the serum level of vitamin D was lower in schizophrenic patients than in controls ($p = 0.035$), and serum homocysteine levels were higher in the schizophrenic group than in controls ($p < 0.001$). Vitamin D levels in patients with schizophrenia were significantly correlated with the overall assessment of extrapyramidal symptoms ($r = 0.35$, $p = 0.04$). However, no significant relationship existed between vitamin D and homocysteine levels and PANSS results ($p > 0.05$).

Conclusion: Serum levels of vitamin D and homocysteine were significantly lower and higher in schizophrenic patients than in the control group. Improvement of extrapyramidal symptoms in schizophrenic patients had a direct and significant relationship with serum vitamin D.

Keywords: Homocysteine, Vitamin D, Schizophrenia, Biomarker, Extrapyramidal, Iran

Introduction

More than 50 million people worldwide have schizophrenia, the most severe and costly disease due to the prevalence of refractory symptoms [1]. Schizophrenia is a destructive disease characterized by frequent recurrences, cognitive decline, and emotional and functional disabilities. This disorder includes positive

*Correspondence: Psychiatric.disordes@yahoo.com

² BSN, Student research committee, Golestan University of Medical Sciences, Gorgan, Iran

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(hallucinations, delusions) and negative (emotional turmoil, apathy) symptoms and cognitive impairments highly resistant to drug treatment [2, 3]. Schizophrenia is a severe psychiatric disorder of unknown origin. Many studies have examined the biological process of the disease over the years [4]. Previous studies have assessed various schizophrenia components, including vitamin D, folate levels, vitamin B12, and homocysteine [5].

Homocysteine, a sulfur-containing amino acid, is involved in the methionine cycle, affecting brain development through multiple cellular pathways [6]. There is evidence that homocysteine levels are associated with psychiatric disorders such as Alzheimer's disease [7], affective disorders, and schizophrenia [8–10]. Elevated plasma homocysteine may be a highly toxic metabolite for the brain and a risk factor for cardiovascular and other diseases, including heart attack, carotid stenosis, cerebral hemorrhage, dementia, bipolar disorder, depression, and Parkinson's disease [5, 11]. Several studies have suggested an association between homocysteine and schizophrenia and reported elevated serum homocysteine levels in acute and chronic schizophrenia, which may play a role in its psychopathology [12, 13].

On the other hand, vitamin D is a unique neurohormone that may play an essential role in the onset of psychiatric diseases [14]. However, the association of vitamin D with psychiatric disorders is not well understood. Vitamin D receptors are widely expressed in the human brain. Vitamin D regulates several pathways of neurotransmitter transmission, including serotonin, dopamine, glutamine, and norepinephrine [15]. In this case, it is not far from the mind that low vitamin D levels are associated with various mental illnesses such as schizophrenia, depression, attention deficit hyperactivity disorder, and autism spectrum disorder [16, 17].

Although much is known about homocysteine and vitamin D levels in patients with schizophrenia, a few studies have assessed their relationship with schizophrenia, especially among Iranians [18, 19].

We hypothesized that vitamin D levels are lower and homocysteine levels are higher in patients with schizophrenia than in the control group. This study aimed to 1) investigate the serum levels of homocysteine and vitamin D in a north Iranian sample of schizophrenia patients compared to healthy controls and 2) assess the relationship between serum levels of vitamin D and homocysteine and the severity of extrapyramidal side effects and positive/negative syndrome in schizophrenia patients.

Method

Study design

A case–control study was conducted at Panj-Azar hospital in Gorgan, north of Iran, from May 2021 to July 2021.

Participants

Thirty-three participants with no known mental illnesses were recruited as the control group and 33 schizophrenic patients as the case group, matched for age and sex.

Eligibility criteria

The inclusion criteria included a) age over 18 years, b) schizophrenia confirmed by a psychiatrist at Panj-Azar hospital, Gorgan, Iran, using semi-structural interviews based on DSM-V criteria, c) no other physical or psychiatric illnesses in patients diagnosed with schizophrenia, d) undergoing treatment with atypical antipsychotics, and e) no psychiatric symptoms such as depression or history of psychiatric illness in the family in the control group. The exclusion criteria were a) another psychiatric illness, b) substance use disorder, c) metabolic disorder affecting serum vitamin D levels, and d) vitamin supplements affecting serum homocysteine and vitamin D.

Sample size

The sample size was calculated using Eq. 1, considering the power of 80% and type 1 error of 5%.

$$n = \frac{(s_1^2 + s_2^2) * (z_{1-\frac{\alpha}{2}} + z_{1-\beta})^2}{d^2} \quad (1)$$

According to Yanchi et al. [2], the total sample size was estimated at 66 people. Due to the outbreak of the coronavirus pandemic, the number of referrals to the hospital's psychiatric department was meager, and we had to use a convenience sampling method.

Psychiatric evaluations

Demographics and clinical information of the participants were collected through a checklist, including gender, age, BMI, education, and marital status. All information was obtained through face-to-face interviews. All diagnostic symptom evaluations were performed by the same psychiatrist using the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) [20] and Simpson-Angus Extrapyramidal Side Effects Scale (SAS) [21]. In short, the PANSS measures the severity of symptoms in patients with schizophrenia and evaluates the positive and negative symptoms of psychosis. The items were divided into five areas: Positive factor (P1, P3, P5, G9), Negative factor (N1, N2, N3, N4, N6, G7), Disorganized/concrete factor (P2, N5, G11), Excited factor (P4, P7, G9, G14), and Depressed factor (G2, G3, G6) by Wallwork et al. based on the original version [22]. The items scored 1 (asymptomatic) to 7 (significantly symptomatic). This questionnaire is valid and reliable in Iran [23]. The SAS assesses the severity of extrapyramidal side effects in

patients with schizophrenia. The rater asks the patient to perform 10 tasks and rates responses on a scale of 0–4 (normal to severe). Its validity and reliability were measured and confirmed in Iran [24].

Blood collection

A venous blood sample (3 cc) was collected from each patient in a tube containing silicate gel to test serum levels of homocysteine and vitamin D. The samples were then stored at -20 °C. After the complete collection of samples, homocysteine and then vitamin D were evaluated in a thigh. The participant’s blood was collected immediately after they answered the questions.

Homocysteine and vitamin D measurement

The ARA TECH kit measured serum vitamin D levels, and the BIOREXFARS kit measured serum homocysteine levels. According to ARA TECH’s vitamin D level standards, the participants were divided into four sub-groups: less than 10 as deficient, 10–30 as insufficient, 30–100 as normal, and more than 100 as toxic. According to the given criteria, the homocysteine levels of the participants in the BIOREXFARS kit were divided into normal (less than 13) and toxic (more than 13).

Statistical analysis

Data are expressed as means and standard deviations. The Mann–Whitney test compared the two groups, and the Kruskal–Wallis test compared the means of more than two groups. Spearman’s correlation test examined

the relationship between quantitative variables. Statistical tests were performed using SPSS version 16 software. The significance level was set at a *p*-value < 0.05. No data was missed because the interviewer collected the information.

Ethical consideration

This study was conducted after obtaining ethical approval (IR.GOUMS.REC.1400.010) from the Golestan University of Medical Sciences.

Results

During the data collection period, 40 patients with schizophrenia were identified. Three patients were excluded due to a lack of informed consent to participate, and four were excluded due to the lack of required criteria. Overall, 33 patients completed the study (Fig. 1).

The demographic characteristics of the participants are shown in Table 1. The case and control groups were closely matched for potential confounders, including age and gender. However, marital status and BMI differed significantly between the two groups (*p* = < 0.001 and 0.003, respectively).

Comparison of serum levels of vitamin D and homocysteine between schizophrenic patients and healthy controls

Of all the participants, 66.7% (*n* = 44) had deficient levels, 27.3% (*n* = 18) had insufficient levels, and 6.1% (*n* = 4) had normal levels of vitamin D. None had vitamin D




Table 1 Demographic and laboratory characteristics of participants

Variables	Schizophrenia (n = 33)	Control (n = 33)	P-value
Gender			
Male	25 (75.8%)	25 (75.8%)	0.99
Female	8 (24.2%)	8 (24.2%)	
Marital status			
Single	19 (57.6%)	6 (18.2%)	0.001
Married	14 (42.4%)	27 (81.8%)	
Educational level			
High school	17 (51.5%)	11 (33.3%)	0.056
Diploma	13 (39.4%)	13 (39.4%)	
University	3 (9.1%)	9 (27.3%)	
BMI (kg/m ²)			
Normal (18.5–23.9)	20 (60.6%)	8 (24.2%)	0.003
Overweight (24.0–27.9)	10 (30.3%)	17 (51.5%)	
Obesity (≥ 28.0)	8 (24.2%)	8 (24.2%)	
Age (year)	40 (34–47)	39 (28.5–49.5)	0.77
Vitamin D (µg/dl)	5.3 (1.75–9.65)	9.1 (4.5–19.5)	0.035
< 10	25 (75.8%)	19 (57.6%)	0.107
10.1–30	7 (21.2%)	11 (33.3%)	
30.1–100	1 (3%)	3 (9.1%)	
Homocysteine (µg/dl)	12.4 (10.95–16.2)	7.2 (5.5–9.6)	< 0.001
13 ≥	17 (51.5%)	30 (90.9%)	< 0.001
13 <	16 (48.5%)	3 (9.1%)	

Values are presented as n (%), median and interquartile range (1st IQR- 3rd IQR)

BMI Body mass index

Significant at *p* < 0.05 compared to the control group

toxicity. The difference between the two groups was statistically significant, and the serum level of vitamin D was lower in schizophrenic patients than in controls (*p* = 0.035) (Table 1).

Additionally, 47 (71.2%) participants had normal homocysteine levels, and 19 (28.8%) had toxic levels. The difference between the two groups was statistically significant, and serum homocysteine levels were higher in the schizophrenic group than in the control group (*p* < 0.001) (Table 1).

Correlation between serum levels of vitamin D and homocysteine

The Spearman correlation test revealed an inverse and significant relationship between vitamin D serum levels and homocysteine (*r* = -0.0258, *p* < 0.05).

Results of SAS and PANSS questionnaires

Data obtained from questionnaires completed by patients with schizophrenia are presented in Table 2. There was a significant association between the positive factor of PANSS and SAS (*r* = 0.347, *p* = 0.04). The data showed no significant relationship between

Table 2 Relationship between the results of the questionnaires and laboratory parameters in the group of schizophrenics

	Median ± IQR	Vitamin D		Homocysteine	
		r	p-value	r	p-value
SAS	3 ± 3.5	0.355	0.04	-0.174	0.33
P-PANSS	16 ± 4	0.0	1	-0.214	0.23
N-PANSS	16 ± 5.5	0.116	0.52	0.103	0.56
Disorganized/concrete	8 ± 2.5	-0.164	0.36	-0.122	0.49
E-PANSS	18 ± 4.5	-0.2	0.26	0.744	0.059
D-PANSS	9 ± 4	0.278	0.11	0.24	0.17

SAS Simpson-Angus Extrapyramidal Side Effects Scale, P-PANSS Positive PANSS, N-PANSS Negative PANSS, E-PANSS Excited factor, D-PANSS Depressed PANSS

vitamin D and homocysteine levels and the PANSS factors (*p* > 0.05). As shown in Table 2, only vitamin D levels in patients with schizophrenia were significantly correlated with the overall assessment of extrapyramidal symptoms (*r* = 0.35, *p* = 0.04). None of the demographic characteristics had a significant relationship with the PNASS and SAS factors (*p* > 0.05).

Discussion

Serum vitamin D and homocysteine levels were significantly lower and higher in schizophrenic patients than in the control group. Consistent with our findings, a meta-analysis reported that patients with schizophrenia had lower vitamin D levels than healthy subjects or other psychiatric patients. Furthermore, a higher incidence of schizophrenia occurred in people with lower vitamin D. Therefore, we can understand a relationship between vitamin D and schizophrenia, but the cause remains unclear [25]. In agreement with our results, many studies reported that 55% to 65% of schizophrenia patients had vitamin D deficiency; in other words, studies report lower vitamin D levels in people with schizophrenia than in healthy people [26–28]. In contrast, studies showed that vitamin D serum levels were low but not statistically significant in patients with schizophrenia compared to healthy individuals [29, 30]. This difference in results may be due to the non-clinical study population or different ethnic groups.

As mentioned, serum homocysteine levels were significantly higher in patients with schizophrenia than in healthy people. In line with our results, a study of 760 schizophrenic patients reported that schizophrenic patients with depressive symptoms had elevated homocysteine levels compared to those without these symptoms [31]. Elevated homocysteine levels have been widely reported in schizophrenia and major depressive disorder [32–34]. The cause of elevated plasma homocysteine in schizophrenic patients is unclear, but studies have shown that malnutrition, coffee drinking, smoking, and inactivity can lead to elevated homocysteine levels [35]. Inadequate intake of vitamins B2, B6, and B12 is also a cause of hyperhomocysteinemia. Lack of vitamins B12 and B2 interferes with homocysteine remethylation, and vitamin B6 deficiency slows down absorption [36]. Due to the complications associated with hyperhomocysteinemia mentioned in the studies and the significantly high homocysteine levels in schizophrenic patients, action must be taken to lower homocysteine levels.

Our findings showed no association between vitamin D and homocysteine and the severity of positive and negative symptoms. After eight weeks of follow-up, there was no difference between vitamin D and placebo in terms of mental illness severity or metabolic status [3]. Bruins et al. reported the same results [37]. However, Rizki et al. [38], like Song et al. [19], found a significant correlation between positive and negative PANSS scores and homocysteine levels. This difference in results may be due to the low sample size of our study. Our study also suggested a link between vitamin D and extrapyramidal side effects. According to a literature review, no study had focused on the relationship between vitamin D levels and

extrapyramidal symptoms, making it difficult to discuss this topic. However, several studies have found that high vitamins B12, C, and E can help reduce extrapyramidal symptoms [39, 40].

Our study's interesting finding was the relationship between the PANSS positive factor and the SAS score. Other researchers have found a link between PANSS negative symptoms and SAS score [41, 42]. There may be two causes for this inconsistency in results: the modification made in the negative and positive sections' questions of the PANSS in our study and the other data on medicines used by patients evaluated in prior research, whose information was not obtained in the current study.

This study was conducted for the first time in northern Iran. Vitamin D levels have been reported to be low in healthy people in the region due to the lack of sun exposure, which was even lower in patients with schizophrenia. One of the study's strengths is its methodology, based on the STROBE checklist, and the appropriate control of potential confounders. One of the limitations of this study is the small sample size and failure to collect treatment information, such as duration and medication type. Other limitations were that it did not consider the possible relationship between drug types and doses and vitamin D and homocysteine serum levels. The link between vitamin D levels and extrapyramidal side effects was demonstrated in this study for the first time; however, a firm conclusion regarding this issue cannot be reached owing to a lack of data about medicines taken by the patients. It is recommended that researchers investigate the association between these two factors, taking into account a larger sample and a more extensive inquiry into the type of medicines used and the duration of treatment. Finally, the PANSS was used to assess negative symptoms, which was the study's final limitation. According to a 2021 research by Galderisi et al. [43], the PANSS items cannot adequately explore negative symptoms and should be replaced with alternative questionnaires. However, based on the literature research, we attempted to address this issue by removing the items that generated assessment inaccuracies [22, 43, 44].

Conclusion

Serum homocysteine levels were significantly higher in schizophrenic patients than in the general population. Also, serum vitamin D levels were significantly lower in schizophrenic patients than in the general population. Improving extrapyramidal symptoms in schizophrenic patients had a direct and significant relationship with serum vitamin D. We recommend nutritional supplements to improve serum vitamin D and homocysteine levels and monitor them in patients' sera.

Abbreviations

PANSS: Positive and Negative Syndrome Scale for Schizophrenia; SAS: Simpson-Angus Extrapyramidal Side Effects Scale; GP: General Psychopathology; cc: Cubic centimeter; °C: The degree Celsius.

Acknowledgements

The authors would like to thank the Psychiatry and Behavioral Sciences Research Center, 5-Azar Hospital, the voluntary participation and cooperation of all patients in the study.

Authors' contributions

Najmeh Shahini: study concept and design, data collection, and literature review; Seyed Mohammad Mousavi Zade Jazayeri, data collection, literature review, Reza Jahanshahi writing the article, and final approval of the article, and Abdurrahman Charkazi: statistical analysis. The author(s) read and approved the final manuscript.

Funding

This work was researched at the Golestan University of medical science and without any organizational financial support.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

The study was conducted by the Declaration of Helsinki and approved by the ethics committee at Golestan University of Medical Sciences IR.GOUMS. REC.1400.010. All participants were informed that participation is voluntary and reassured that responses would remain confidential. Informed written consent was also obtained from all participants filling in the questionnaires. Participants may withdraw from the trial at any point without any penalty and will not receive compensation for taking part. In the study, personal information about participants collected during the consent/data collection processes is stored securely.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Golestan Research Center of Psychiatry (GRCP), Golestan University of Medical Sciences, Gorgan, Iran. ²BNS, Student research committee, Golestan University of Medical Sciences, Gorgan, Iran. ³Health Education and Promotion, Faculty of Health, Environmental Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Received: 28 May 2022 Accepted: 7 September 2022

Published online: 04 November 2022

References

- Ghaderi A, Banafshe HR, Mirhosseini N, Moradi M, Karimi M-A, Mehrzad F, et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. *BMC Psychiatry*. 2019;19(1):1–10.
- Yazici E, Mutu Pek T, Guzel D, Yazici AB, Akcay Ciner O, Erol A. Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients. *Nord J Psychiatry*. 2019;73(3):178–84.
- Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, et al. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. *EBioMedicine*. 2017;26:138–45.
- Fan N, Tan Y, Yang F, Tian L, Chen S, Li J, et al. Effect of risperidone on serum homocysteine levels in first-episode, drug-naive patients with schizophrenia. *Neurosci Lett*. 2017;650:168–73.
- Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. *Psychiatry Res*. 2010;175(1–2):47–53.
- Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. *J Neurosci Res*. 2002;70(5):694–702.
- Shirafuji N, Hamano T, Yen S-H, Kanaan NM, Yoshida H, Hayashi K, et al. Homocysteine increases tau phosphorylation, truncation and oligomerization. *Int J Mol Sci*. 2018;19(3):891.
- Zhou S-J, Zhang L-G, Chen H-M, Li J-Y, Li R, Zhang X-M, et al. Prevalence and clinical-demographic correlates of hyperhomocysteinemia in inpatients with bipolar disorder in a Han Chinese population. *Psychiatry Res*. 2018;259:364–9.
- Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders—focus on cognition. *Front Behav Neurosci*. 2014;8:343.
- Safaei M, Manteghi AA, Shahini N, Mohammadpour AH. Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics. *Med J Islam Repub Iran*. 2019;33:114.
- Kim TH, Moon SW. Serum homocysteine and folate levels in Korean schizophrenic patients. *Psychiatry Investig*. 2011;8(2):134.
- Dietrich-Muszalska A, Malinowska J, Olas B, Glowacki R, Bald E, Wachowicz B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. *Neurochem Res*. 2012;37(5):1057–62.
- Petronijević ND, Radonjić NV, Ivković MD, Marinković D, Piperski VD, Đuričić BM, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(8):1921–6.
- Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 α -hydroxylase in human brain. *J Chem Neuroanat*. 2005;29(1):21–30.
- Kesby JP, Turner KM, Alexander S, Eyles DW, McGrath JJ, Burne TH. Developmental vitamin D deficiency alters multiple neurotransmitter systems in the neonatal rat brain. *Int J Dev Neurosci*. 2017;62:1–7.
- Groves NJ, McGrath JJ, Burne TH. Vitamin D as a neurosteroid affecting the developing and adult brain. *Annu Rev Nutr*. 2014;34:117–41.
- Sharif MR, Madani M, Tabatabaei F, Tabatabaee Z. The relationship between serum vitamin D level and attention deficit hyperactivity disorder. *Iran J Child Neurol*. 2015;9(4):48.
- Dibajipour AS, Sedghi G. Evaluating the efficacy of Vitamin D add-on therapy on treatment of positive, negative and cognitive symptoms in patients with chronic schizophrenia; a double blind clinical trial. *J Med Council Islamic Rep Iran*. 2020;37(3):171–7.
- Jamilian HR, Baqerzadeh K, Nazeri QZ. Comparison of serum levels of vitamin D, parathyroid hormone, calcium and phosphorus in schizophrenia, major depression and healthy individuals. *J Arak Univ Med Sci*. 2011;14(6):19–26.
- Kay SR, Opler LA, Lindenmayer J-P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. *Psychiatry Res*. 1988;23(1):99–110.
- Simpson G, Angus J. A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand*. 1970;45(S212):11–9.
- Wallwork R, Fortgang R, Hashimoto R, Weinberger D, Dickinson D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. *Schizophr Res*. 2012;137(1–3):246–50.
- Ghamari Givi H, Moulavi P, Heshmati R. Exploration of the factor structure of positive and negative syndrome scale in schizophrenia spectrum disorder. *J Clin Psychol*. 2010;2(2):1–10.
- Fakhri A, Pakseresht S, Haghdoost MR, Hekmatkhan N, Torkashvand M, Ghorbanzadeh B. Memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study. *Acta Medica Iranica*. 2016;54:696–703.
- Ji Zhu, Luo WW, Cheng X, Li Y, Zhang QZ, Peng WX. Vitamin d deficiency and Schizophrenia in adults: a systematic review and meta-analysis of observational studies. *Psychiatr Res*. 2020;288:112959.
- Ristic S, Zivanovic S, Milovanovic DR, Janjic V, Djokovic D, Jovicevic A, et al. Vitamin D deficiency and associated factors in patients with mental disorders treated in routine practice. *J Nutr Sci Vitaminol*. 2017;63(2):85–95.

27. Okasha TA, Sabry WM, Hashim MA, Abdeen MS, Abdelhamid AM. Vitamin D serum level in major depressive disorder and schizophrenia. *MECP*. 2020;27(1):1–8.
28. Valipour G, Saneei P, Esmailzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. *J Clin Endocrinol Metab*. 2014;99(10):3863–72.
29. Ikonen H, Palaniswamy S, Nordström T, Järvelin M, Herzog K, Jääskeläinen E, et al. Vitamin D status and correlates of low vitamin D in schizophrenia, other psychoses and non-psychotic depression—The Northern Finland birth cohort 1966 study. *Psychiatry Res*. 2019;279:186–94.
30. Clelland JD, Read LL, Drouet V, Kelly A, Duff KE, Nadrich RH, et al. Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of association. *Schizophr Res*. 2014;156(1):15–22.
31. Zhang Y, Zhao J, Wang W, Fan W, Tang W, Zhang C. Homocysteine, but not MTHFR gene polymorphism, influences depressive symptoms in patients with schizophrenia. *J Affect Disord*. 2020;272:24–7.
32. Hotnauli Y, Loebis B, Husada MS, Nasution NM, Effendy E. The Correlation between the Indonesian Version of Montreal Cognitive Assessment and Homocysteine Levels in Batakese Male with Schizophrenia in Prof. DR. M. Ildrem Psychiatric Hospital Medan. *Open Access Maced J Med Sci*. 2021;9(T3):135–7.
33. Huang Y, Wu K, Li H, Zhou J, Xiong D, Huang X, et al. Homocysteine level, body mass index and clinical correlates in Chinese Han patients with schizophrenia. *Sci Rep*. 2020;10(1):1–8.
34. Bhatia P, Singh N. Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression. *Fundam Clin Pharmacol*. 2015;29(6):522–8.
35. Schneede JN, Refsum H, UELAND P. Biological and environmental determinants of plasma homocysteine. In: *Seminars in thrombosis and hemostasis*. 2000; 26(03):263–280. Copyright© 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
36. Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. *Arch Pharmacol Res*. 2018;41(4):372–83.
37. Bruins J, Jörg F, van den Heuvel E, Bartels-Velthuis A, Pijnenborg G, Bruggeman R. The relation of vitamin D, metabolic risk and negative symptom severity in people with psychotic disorders. *Schizophr Res*. 2018;195:513–8.
38. Rizki R, Effendy E, Camellia V, Subastian F. Correlation between positive and negative syndrome scale (PANSS) scores and homocysteine levels in men with schizophrenia batakese tribe at psychiatric hospital of prof. M. ILDREM MEDAN. *PalArch's J Archaeol Egypt/Egyptology*. 2020;17(6):1505–18.
39. Burada E, Marinescu I, Rogoveanu OC, Dobrescu A, Taisescu C, Burada F, et al. Vitamin B12 blood level is correlated with drug-induced extrapyramidal symptoms in schizophrenic patients. *Rev Chim*. 2019;70(2):630–2.
40. Chia SC, Henry J, Mok YM, Honer WG, Sim K. Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence. *J Neural Transm*. 2015;122(12):1721–32.
41. Weng J, Zhang Y, Li H, Shen Y, Yu W. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia. *Gen Psychiatr*. 2019;32(1):e100026.
42. Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J, et al. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. *Eur Neuropsychopharmacol*. 2014;24(9):1500–5.
43. Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. *Eur Psychiatry*. 2021;64(1):e21.
44. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. *The Lancet Psychiatry*. 2018;5(8):664–77.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

